New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

West Pharmaceutical Services, Inc.

WST

Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+57.3%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

390.56 6.13 −1.55%

After hours trading: 390.30, down 0.07%, last trade 5:54pm Eastern.

Market cap
$27.6B
P/E
43.5×
Fwd P/E FY26e
44.6×
Dividend yield
0.24%
F-score
8/9
ROIC
18.0%
Net debt / EBITDA
−0.8×
Payout ratio
0.1×

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

Of every $100 of revenue, $24.47 was left as profit. Gross margin has risen two quarters running, from 35.1% to 39.7%. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue874.5100.0%
Cost of revenue−527.1−60.3%
Gross profit347.439.7%
Research & development−18.3−2.1%
Selling, general & admin−112.9−12.9%
Other operating costs+51.25.9%
Operating income267.430.6%
Income tax−58.0−6.6%
Other items+4.30.5%
Net income214.024.5%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$805M$845M$872M$874M
Operating income$157M$177M$179M$267M
Net income$132M$139M$154M$214M
Net margin (right axis)16.4%16.4%17.7%24.5%
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more quarters

805.00 844.90 872.30 874.50
Revenue Growth
7.51% 21.05% 13.80% 8.69%
Gross Profit
303.90 296.40 329.20 347.40
Operating Income
156.60 177.10 179.10 267.40
EBT
161.50 180.10 180.10 267.70
Income after Tax
128.20 135.40 147.90 209.70
Net Income Common
132.10 138.80 154.00 214.00
EPS (Diluted)
1.82 1.92 2.15 3.02
Shares (Diluted, Weighted)
72.70 72.40 71.30 70.80
Gross Margin
37.75% 35.08% 37.74% 39.73%
EBIT Margin
19.45% 20.96% 20.53% 30.58%
Net Profit Margin
16.41% 16.43% 17.65% 24.47%
EBITDA
203.60 222.30 225.30 313.30
EBIT
156.60 177.10 179.10 267.40

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026